Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies

MLA

Simon Daenen, et al. “Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies.” PharmacoEconomics, vol. 29, Sept. 2011, pp. 737–51. EBSCOhost, https://doi.org/10.2165/11588370-000000000-00000.

APA

Simon Daenen, Maarten J. Postma, Petros Pechlivanoglou, & Robin de Vries. (2011). Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies. PharmacoEconomics, 29, 737–751. https://doi.org/10.2165/11588370-000000000-00000

Chicago

Simon Daenen, Maarten J. Postma, Petros Pechlivanoglou, and Robin de Vries. 2011. “Cost Benefit and Cost Effectiveness of Antifungal Prophylaxis in Immunocompromised Patients Treated for Haematological Malignancies.” PharmacoEconomics 29 (September): 737–51. doi:10.2165/11588370-000000000-00000.